BASELINE LDL-C AND CLINICAL OUTCOMES WITH ADDITION OF EZETIMIBE TO STATIN IN 18,144 PATIENTS POST ACS
Explore this paper's citation graph
Summary
The IMPROVE IT trial randomized 18,144 patients post-ACS to either ezetimibe or placebo, on a background of simvastatin 40-80 mg, and compared clinical benefit to treatment benefit.
- Type
- article
- Published
- 2015-03-17
- Cited by
- 8
- References
- 0
- Access
- Open access
- OpenAlex
- https://openalex.org/W1998441750
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:71323078
Keywords
Medicine, Ezetimibe, Statin, Internal medicine, Ldl cholesterol
References
No references recorded for this paper.
Cited by
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
- Statin combination therapy and cardiovascular risk reduction.
- A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- Evolocumab and clinical outcomes in patients with cardiovascular disease
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
- Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
- Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Related papers
- Comparison of signal detection between statin and statin/ezetimibe fixed-dose combination using the Korea Adverse Events Reporting System Database, 2005 - 2016 .
- Attainment of accaha recommended LDL C lowering with statin and ezetimibe statin therapies
- Statin plus Extended Release Niacin is More Effective than Statin plus Ezetimibe in Reducing CIMT
- Low‐density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real‐world evidence
- A comparison of the attainment of guideline-recommended LDL-C lowering with statin and ezetimibe+statin therapies.
- Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
- Effect of High-Dose Statin Versus Low-Dose Statin Plus Ezetimibe on Endothelial Function
- A Comparison of the Attainment of Guideline-Recommended LDL-C Lowering With Statin and Ezetimibe+Statin Therapies
- Evidence for Cholesterol Hyperabsorbers and Hyperproducers Based on Comparative Low-Density Lipoprotein Reductions Achieved by Ezetimibe Versus Statins